Cytodyn Inc (CYDY)

[kgromax]

Unless they consider that the primary endpoint failure is not a material event, given that a deeper analysis of the secondary endpoints may reveal something positive anyway.

That may be what they did for the previous COVID trial (CD10): given the important delays there to reveal the primary endpoint had been missed, it is entirely possible (only the SEC could check the delays there, determining who knew what internally and when) that they have skipped the material event qualification for the primary endpoint, arguing internally that the secondary endpoints were as important.

After all, that's what they tried to make the shareholders believe, that NEWS2 (one secondary endpoint datamined in a sea of missed endpoints) was a good news. Until the infamous Christmas Eve Dump where they finally admitted the CD10 results would "not support an eIND".